Prognosis And Survival Analysis Of HCC Patients Treaitu With TACE

Objective:Primary hepatocellular carcinoma(PHC) is one of the most common cause of cancer-related death in the world.Due to tumor was found later, lesion progress fast and other reasons, only 20% of the patients with clear diagnosis can be treated with radical resection treatment, most patients can be treated only by non-surgical treatment.With the development of interventional diagnosis and treatment level, interventional therapy has become one of the most important treatment approaches for PHC patients in China, the patients survival time had prolonged and their quality of life had improved.Many patients still could not get the standardized treatment, their longterm survival time were not long.Because of transcatheter arterial chemoembolization(TACE) is the most important way of interventional therapy,this study was aim to evaluate the factors affecting the prognosis and survival time of PHC treated with TACE,and what are protective and dangerous factors were cleared, thus better clinical treatment selection and prognostic judgement to provide basis for clinical diagnosis and treatment could be obtained, to make patients get better treatment effect and reduce the patient’s family and the country’s economic burden.Methods: The medical records of 382 patients treated with TACE from Jan.2007 to Dec.2011 in Dept of Interventional Radiology of the Provincial Hospital were retrospectively reviewed, the ones whose survival time beyond 3 years were 89.Through the combination of outpatient, hospital and telephone to follow-up patients, control the patient’s treatment and follow-up of indicators strictly and so on.then selected the related variables accompany single and multiple regression analysis, and calculated the survival curve with Kaplan-Meieris to compare the survival differences between them,factors affecting prognosis and survival time of patients after TACE were obtained.Results: All of the patients, whose survival time beyond 3 years, were 89. Among them, those patients whose survival time beyond 4 years were 73(19.1%), those beyond 5 years were 31(8.1%), those beyond 7 years were 14(3.66%). By single-factor analysis,background of hepatitis B cirrhosis,tumor stage,type,Child-Pugh,AFP,tumor thrombus in portal vein, arterial-portal/venous fistula and age had certain influence on the prognosis and survival time of the PHC patients treated with TACE,while multiplefactor analysis showed that stage,tumor thrombus in portal vein,age and hepatitis B cirrhosis had obvious influence on them, the differences were statistically significant.Conclusion:Tumor stage,thrombus in portal vein,age and hepatitis B cirrhosis have significant influence on the prognosis and survival time of PHC patients treated with TACE.According to different age, physical condition and the specific situation of the patients to formulate individualized treatment plan, grasp indications in clinical practice reasonably, review on schedule and regularly, and process complications timely can effectively prolong patient survival time.